Ahn Daniel H, Bekaii-Saab Tanios
Division of Hematology/Medical Oncology, Mayo Clinic, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.
Biomedicines. 2017 Mar 4;5(1):10. doi: 10.3390/biomedicines5010010.
Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell apoptosis without harming normal tissues, thus offering a promising tool in the armamentarium for cancer therapy. While this approach has garnered much interest over the past several decades, there has not been significant headway across various tumor types. The recent approval of talimogene laherparepvec, a second-generation oncolytic herpes simplex virus type-1, for the treatment of metastatic melanoma, confirms the therapeutic potential of oncolytic viral therapy. Herein, we will highlight and review the role of oncolytic viral therapy in gastrointestinal malignancies while discussing its limitations and potential alternative mechanisms to improve its treatment efficacy.
溶瘤病毒疗法是治疗胃肠道恶性肿瘤的一种新型治疗策略。溶瘤病毒，包括基因工程病毒和天然存在的病毒，能够在肿瘤细胞中选择性复制并诱导其凋亡，而不损害正常组织，从而为癌症治疗提供了一种有前景的武器。尽管在过去几十年里这种方法引起了广泛关注，但在各种肿瘤类型中尚未取得显著进展。第二代溶瘤单纯疱疹病毒1型塔利莫基因拉赫帕里韦克最近被批准用于治疗转移性黑色素瘤，证实了溶瘤病毒疗法的治疗潜力。在此，我们将重点介绍和回顾溶瘤病毒疗法在胃肠道恶性肿瘤中的作用，同时讨论其局限性以及提高治疗效果的潜在替代机制。
